Objective To determine whether left ventricular assist device (LVAD) treatment in children with heart failure would result in the modification of molecular pathways involved in heart failure pathophysiology.
T he b-adrenergic pathway plays an essential role in the regulation of cardiac function. The 2 main receptors in the heart are the b1-adrenergic receptor (b1-AR) and the b2-adrenergic receptor (b2-AR). 1 In adults with heart failure, elevations in circulating catecholamines lead to chronic stimulation of b-adrenergic receptors (b-ARs), resulting in b1-AR downregulation and desensitization caused by an increase in receptor phosphorylation by the up-regulated G protein-coupled receptor kinase-2 (GRK2). 1 During end-stage heart failure, mechanical circulatory support devices such as left ventricular assist devices (LVADs) are used as a form of therapy when drug treatments are no longer effective. Unloading the heart can lead to reverse remodeling such as improved calcium homeostasis and cycling in myocytes as well as alterations in gene expression in various components of the b-adrenergic system. 2 Heart failure in children is not as common as in adults; therefore, there is a lack of focused research specific to this patient group. Previous work has demonstrated significant differences in the regulation of the b-adrenergic system and a number of downstream molecules, suggesting that the molecular effects of heart failure and interventions in adults cannot be extrapolated to children. [3] [4] [5] There also is no evidence that drugs such as b-blockers are as efficacious when used for 
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pediatric patients with heart failure [6] [7] [8] ; however, as seen in adults, there is an improvement in structure and function in pediatric hearts implanted with LVADs. 9, 10 A study on acute LVAD treatment of pediatric patients reveals that some genes are regulated differentially after 10 days of LVAD treatment; however, the study did not address changes in the GRK regulation of the b-adrenergic system, the pathologic gene program, or phosphorylation of its downstream targets. 11 These data suggest that there are functional and molecular changes occurring in pediatric hearts implanted with LVADs, and we therefore hypothesized that LVAD therapy will modify the b-AR system in children with heart failure. This study analyzes the molecular changes in the left ventricles of pediatric patients implanted with an LVAD and determines whether changes in GRK2 may underlie changes in b-AR expression.
Methods
Human subjects were boys and girls younger than the age of 17 years who donated their hearts to the pediatric transplant tissue bank at the University of Colorado. The study was approved by the institutional review committee, and informed consent was obtained. Nonfailing control hearts were donor hearts not transplanted for technical reasons. Explanted diseased hearts were from children suffering from advanced nonischemic idiopathic dilated cardiomyopathy (IDC) without or with an LVAD. A detailed description of the pediatric patients can be found in the Table (available at www.jpeds.com). At the time of cardiac transplantation, the explanted hearts were cooled immediately in ice-cold oxygenated Tyrode solution in the operating room. The left ventricle was dissected rapidly, flash frozen, and stored at −80°C until further use. The failing and nonfailing groups were age-matched as best as possible to the patients in the failing post-LVAD implantation (F-LVAD) group a priori to mitigate any potential confounding between groups.
The Engel method was used with crude membrane preparations and [ 125 I]-iodocyanopindolol to determine total and b-AR subtype protein expression as previously published by our group. 3, 12 Real-time quantitative polymerase chain reaction of the pathologic gene program was performed as previously described. 13 Primers have been published previously by our group. 3 Data were normalized to the expression of ribosomal RNA 18s.
Western blots were performed as previously described. 3, 14 GRK2 antibody (SC-562, 1:1000) and glyceraldehyde 3-phosphate dehydrogenase (SC-20357, 1:10 000) were purchased from Santa Cruz Biotechnology, Inc (Santa Cruz, California). Phospholamban serine 16 (Ser16) (A010-12, 1:15 000) and threonine 17 (Thr17) (A010-13, 1:15 000) Figure 1 . b-AR density of nonfailing, failing, and F-LVAD. A, Bmax, total receptor density; B, b1-AR density; and C, b2-AR density. Total and b1-AR density in LVAD-treated hearts were similar to nonfailing levels. b2-AR density in LVAD-treated hearts was significantly greater compared with nonfailing and failing levels.
Volume 182 • March 2017 antibodies were purchased from Badrilla (Leeds, United Kingdom). Phospholamban total (05-205, 1:1000) antibody was purchased from Millipore (Billerica, Massachusetts). The horseradish peroxidase (115-035-146) antimouse and antirabbit secondaries were purchased from Jackson ImmunoResearch, Inc (West Grove, Pennsylvania). Antibodies were diluted in 1× TBS (20 mM Tris, 500 mM NaCl, pH 7.5) containing 5% bovine serum albumin and 0.1% Tween. Blots were incubated overnight at 4°C.
Statistical Analyses
The Shapiro-Wilk method was used to determine normality in all continuous data. 15 Data that were not normally distributed were log transformed and retested before analysis. Statistical analysis was performed with Statview software (SAS Institute, Cary, North Carolina). To evaluate for interactions, 2-way ANOVA was performed on all outcomes. Regression analysis was performed when indicated to identify correlations. Statistical significance was set to P < .05, and all data are presented as mean ± SD (mean ± SEM in Figures 1-4) . For logtransformed data, the mean and error measurements are given for the raw data for visual clarity.
Results
The clinical characteristics of each cohort are described in the Table. Importantly, there was no significant difference in age between failing and F-LVAD or nonfailing and F-LVAD; however, the nonfailing cohort average age was greater than the patients in the failing cohort (P = .01). Although 4 different LVADs were used, the overwhelming majority of the devices were pulsatile-flow EXCOR Berlin Hearts (Berlin Heart, Berlin, Germany), and only 2 were continuous-flow devices.
b-AR Density
Total b-AR expression (Bmax) in the failing hearts (67.2 ± 11.5 fmol/mg) was lower compared with nonfailing hearts (99.5 ± 27.7 fmol/mg, P = .01); however, Bmax was similar to nonfailing in patients with F-LVAD (104.0 ± 38.7 fmol/ mg) (Figure 1, A) . Similar results were seen for the b1 receptor (nonfailing 83.0 ± 23.0 fmol/mg; failing 52.2 ± 10.3 fmol/ mg; F-LVAD 76.5 ± 32.1 fmol/mg; nonfailing to failing P = .005 and F-LVAD to failing P = .03) (Figure 1, B) . b2-AR was significantly greater in patients with F-LVAD (27.5 ± 12.0 fmol/ mg, P < .005) compared with both nonfailing (16.4 ± 6.1 fmol/ mg) and failing (15.0 ± 4.2 fmol/mg) (Figure 1, C) .
GRK2 Protein Levels
GRK2 protein expression was significantly greater in the failing pediatric heart (5.6 ± 9.0, Figure 2) . Expression in the F-LVAD group (1.0 ± 1.3) was significantly lower than the failing group and no different from GRK2 expression in the nonfailing hearts (1.0 ± 0.493).
Phospholamban Phosphorylation
There was no significant difference in total phospholamban protein levels between the 3 groups (data not shown); however, there was significantly greater Ser16 phosphorylation (protein kinase A site) in patients with F-LVAD (7.7 ± 11.7, P < .05) compared with nonfailing (1.0 ± 1.2) and failing (0.8 ± 1.0) (Figure 3, A) . Although phosphorylation at Thr17 (the calcium calmodulin kinase II site) appeared lower in patients in the F-LVAD cohort (0.6 ± 0.5), the change was not significant compared with patients in the nonfailing (1.0 ± 1.2) and failing (1.3 ± 1.7) cohorts (Figure 3, B) . A regression analysis was performed to determine whether age, time on LVAD, medical therapy, b-AR density, or GRK2 levels were responsible for the variability in phospholamban phosphorylation within this population, but no correlation was found (data not shown).
Changes in Pathologic Gene Program
Messenger RNA Atrial natriuretic factor levels were significantly greater (P = .03) in failing hearts (2.8 ± 3.6) compared with nonfailing (1.0 ± 1.8) but were similar between nonfailing and patients with F-LVAD (0.6 ± 0.8). Although there was no significant difference in brain natriuretic peptide levels between nonfailing (1.0 ± 1.6) and failing hearts (0.6 ± 0.7), there was significantly less in F-LVAD hearts (0.1 ± 0.1) compared with nonfailing (P = .05) and failing (P = .02) samples. Sarcoendoplasmic reticulum calcium 
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Volume 182 transport ATPase (SERCA) and a-myosin heavy chain (aMyHC) were both significantly lower in the failing hearts (SERCA: 0.4 ± 0.3; a-MyHC: 0.1 ± 0.1) compared with nonfailing (SERCA: 1.0 ± 0.7, P = .03; a-MyHC: 1.0 ± 0.6, P < .0001), and b-MyHC was significantly greater in the failing heart (1.5 ± 0.3) compared with nonfailing (1.0 ± 0.6, P = .03); however, there was no effect of LVAD therapy, and expression of these genes remained significantly different from nonfailing levels (SERCA: 0.3 ± 0.2, P = .003; a-MyHC: 0.2 ± 0.2, P < .0001; b-MyHC 1.6 ± 0.7, P = .01).
Discussion
Mechanical circulatory support has become an important tool for the treatment of heart failure. Adjunctive therapies may be especially important for children because drug treatments lack the same efficacy as seen in adults and there are far fewer donor hearts available to children. Therefore, understanding the molecular remodeling produced with LVAD therapy in the failing pediatric heart is necessary. The current study demonstrates for the first time the effect of LVAD treatment on the b-AR expression, phospholamban phosphorylation, and the pathologic gene program of pediatric patients suffering from heart failure. Furthermore, our findings suggest that GRK2 may be responsible for regulation of the b1-AR, but not b2-AR, in pediatric heart failure.
Both pulsatile-and continuous-flow LVADs in adult populations have been demonstrated to normalize total cardiac b-AR and b1-AR densities. 16, 17 Although limitations in our population do not allow us to definitively separate by LVAD type, total b-AR and b1-AR densities also approximate normal levels in children with heart failure after treatment with an LVAD. The broad range of treatment times in our population allowed us to perform a regression analysis (data not shown) that demonstrated a positive correlation between the number of days the patient was treated with changes in total b-AR and b1-AR densities. We have previously demonstrated unique agedependent regulation of the b2-AR with heart failure in children, 3 and the data extend this finding into the LVADtreated population by demonstrating that b2-AR levels were significantly and substantially greater in LVAD hearts compared with both failing and nonfailing hearts. Because the b2-AR is thought to play a cardioprotective role in the heart, 18 a change in this receptor population may underlie age-differences in mechanisms of disease.
In adult heart failure, there is an up-regulation of GRK2 that correlates with the clinical severity of the disease 19 and downregulation of the b1-AR. In adults, interventions that mitigate the disease process, such as b-blockers or LVADs, lower GRK2 and increase b1-AR expression. 16, 20 Our results show that GRK2 levels are significantly greater in pediatric failing hearts but return to nonfailing levels in response to LVAD therapy and correlate with b1-AR expression, providing novel evidence for a similar regulatory process in children. In contrast, the changes in GRK2 expression aren't associated with the changes in b2-AR expression in pediatric patients, suggesting that a different mechanism is responsible for adaptations in this receptor.
Similar to milrinone therapy, 7 Ser16 phosphorylation is significantly greater in the F-LVAD group. The preservation of Ser16 phosphorylation in the absence of milrinone in the children with LVADs strongly suggests a positive remodeling process. In addition, and consistent with a positive remodeling process, atrial natriuretic factor and brain natriuretic peptide levels were significantly lower in the F-LVAD group than in the failing heart on medical therapy alone. These data are similar to the previous gene expression data in children 11 and the response of the failing adult heart to LVAD therapy. 21 Improvement in the natriuretic peptides may be the result of unloading of the left ventricle or positive remodeling.
There were several limitations to this study. First, there are limitations inherent to the cross-sectional study design. We have attempted to control for possible confounding factors through age-matching and limiting our failing population to IDCs. Second, because it is impossible to use "normal" hearts from children, brain dead donor hearts were used as nonfailing controls for this study. Brain death can affect the heart 22 ; however, it is important to note that any changes in AR activation would be more likely to bias our results against finding a difference. Third, there were 4 different types of LVADs used to treat patients in this study; however, the overwhelming majority (9/ 11) received the pulsatile Berlin Heart, which makes the result most applicable to this device. A final concern is the potential heterogeneity within the IDC population, as demonstrated in Figure 3 . Despite performing multiple correlations of various clinical variables such as patient medication profile, 
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In conclusion, these studies provide the first insight into the molecular changes that occur in the b-adrenergic pathway, phospholamban phosphorylation, and pathologic gene program in LVAD-treated pediatric failing hearts. These changes are most likely caused by unloading of the heart. Importantly, these results suggest that GRK2 may be a regulatory mechanism for the b1-AR but not the b2-AR in the failing pediatric heart. These changes are indicative of reverse remodeling and suggest that LVADs may have the potential to be used as pathway to recovery. Additional studies will be important to determine whether any of these findings can be used as biomarkers of myocardial recovery or as a means of identifying novel medical adjunctive therapies to promote ventricular recovery and device explant in this population. ■
